Lexaria Bioscience Corp. — Director's Dealing 2022

Oct 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2022-10-12

Reporting Person: BUNKA CHRISTOPHER (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-12	common shares	A	21900	$1.988	Acquired	237812	Indirect
2022-10-13	common shares	A	16600	$2.1	Acquired	254412	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
common shares	273543	Direct
common shares	215912	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants	$10.5	2025-05-06	Common Shares (6667)	6667	Indirect
Stock Options	$5.83	2026-04-26	Common Shares (26000)	32667	Direct
Stock Options	$7.08	2026-06-08	Common Shares (23334)	56001	Direct
Stock Options	$6.23	2026-09-01	Common Shares (15000)	71001	Direct
Stock Options	$2.91	2027-08-29	Common Shares (30000)	101001	Direct